drugset
drugset / Trial / NCT00126763

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

NCT00126763 ↗

Phase 3 Terminated 105 enrolled ZARS Pharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of non-malignant chronic pain.

Timeline

Start
2005-07
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 25 ug Other
Subject Fentanyl Other / unclassified 50 ug Other
Subject Fentanyl Other / unclassified 75 ug Other
Subject Fentanyl Other / unclassified 100 ug Other

Indications

No indication recorded.